Skip to main content

Table 1 Clinico-pathological data of the patients and BM-status at BM1 and BM2 a

From: Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study

 

All patients Number (%)b

BM1 neg Number (%)c

BM1 pos Number (%)c

P valued

BM2 neg Number (%)c

BM2 pos Number (%)c

P valued

Number:

n = 1090

n = 991

n = 94

 

n = 1002

n = 83

 

Age at inclusion (median): 48 (range 23-69)

Menopausal status:

 Pre

592

(55.7)

540

(91.5)

50

(8.5)

0.19

547

(92.7)

43

(7.3)

0.60

 Post

325

(30.6)

287

(88.9)

36

(11.1)

296

(91.6)

27

(8.4)

 Unknown

146

(13.7)

138

(95.2)

7

(4.8)

134

 

11

(7.6)

 Missing

27

 

26

 

1

 

25

(92.4)

2

 

Primary breast cancer surgery:

      

1.00

    

0.29

 Mastectomy

424

(39.4)

384

(91.2)

37

(8.8)

384

(91.2)

37

(8.8)

 Lumpectomy

653

(60.6)

594

(91.2)

57

(8.8)

60612

(93.1)

45

(6.9)

 Missing

13

 

13

     

1

 

pT-status:

      

0.06

    

0.03

 pT 1a + b

67

(6.3)

55

(82.1)

12

(17.9)

65

(97.0)

2

(3.0)

 pT1c

500

(46.7)

451

(90.7)

46

(9.3)

464

(93.4)

33

(6.6)

 pT2

449

(41.9)

418

(93.3)

30

(6.7)

407

(90.8)

41

(9.2)

 pT3

49

(4.6)

44

(91.7)

4

(8.3)

43

(89.6)

5

(10.4)

 pT4

6

(0.6)

6

(100)

0

(0)

5

(83.3)

1

(16.7)

 Missing

19

 

17

 

2

 

18

 

1

 

pN-status:

      

0.59

    

0.009

 pN0

462

(43.3)

424

(92.2)

36

(7.8)

428

(93.0)

32

(7.0)

 pN1

455

(42.6)

408

(89.9)

44

(9.7)

424

(93.8)

28

(6.2)

 pN2

99

(9.3)

93

(93.9)

6

(6.1)

86

(86.9)

13

(13.1)

 pN3

52

(4.9)

46

(88.5)

6

(11.5)

43

(82.7)

9

(17.3)

 Missing

22

 

20

 

2

 

21

 

1

 

Histology:

      

0.02e

    

0.03e

 IDC

888

(82.4)

815

(92.3)

68

(7.7)

821

(93.0)

62

(7.0)

 ILC

106

(9.8)

90

(84.9)

16

(15.1)

92

(86.8)

14

(13.2)

 Others

84

(7.8)

74

(88.1)

10

(11.9)

79

(94.0)

5

(6.0)

 Missing

12

 

12

   

10

 

2

 

Histological grade:

      

0.06

    

0.92

 Grade 1

83

(7.7)

75

(90.4)

8

(9.6)

80

(96.4)

3

(3.6)

 Grade 2

583

(53.9)

520

(89.8)

59

(10.2)

527

(91.0)

52

(9.0)

 Grade 3

404

(37.3)

378

(93.8)

25

(6.2)

376

(93.3)

27

(6.7)

 Unclassified

12

(1.2)

117

(91.7)

1

(8.3)

12

(100)

0

(0)

 Missing

8

   

1

 

7

 

1

 

ER-status:

      

0.20

    

0.69

 Pos

814

(75.2)

737

(91.0)

73

(9.0)

749

(92.5)

61

(7.5)

 Neg

268

(24.8)

250

(93.6)

17

(6.4)

245

(91.8)

22

(8.2)

 Missing

8

 

4

 

4

 

8

   

PR-status:

            

 Pos

701

(64.9)

636

(91.1)

62

(8.9)

0.91

648

(92.8)

50

(7.2)

0.34

 Neg

369

(34.2)

337

(91.6)

310

(8.4)

3359

(91.0)

33

(9.0)

 Unclassified

10

(1.0)

9

(100)

1

(0)

10

(100)

0

(0)

 Missing

10

 

9

       

Endocrine therapy:

      

0.52

    

0.41

 Yes

810

(76.2)

733

(90.8)

74

(9.2)

750

(92.9)

57

(7.1)

 No

253

(23.8)

233

(92.5)

19

(7.5)

230

(91.3)

22

(8.7)

 Missing

27

 

25

 

1

 

22

 

4

 

HER2-statusf:

      

0.46

    

0.84

 Pos

117

(17.4)

109

(94.0)

7

(6.0)

108

(93.1)

8

(6.9)

 Neg

557

(82.6)

507

(91.4)

48

(8.6)

519

(93.5)

36

(6.5)

 Missing

51

 

48

 

2

  

49

    

BM1:

         

 Positive

    

79

(84.0)

15

(16.0)

0.004

 Negative

    

923

(93.1)

68

(6.9)

  1. aAll patients with a BM2 result are presented (column all patients). For the data according to BM1 and BM2 status, patients with a reported result on both analyses, are presented, n = 1085) (also see Figure 1).
  2. bValid percent.
  3. cThe percentages for the BM1 and BM2 analysis, in relation to the clinico-pathological variables.
  4. dFisher Exact test for variables with two categories; Linear-by-Linear Association for variables with more than two categories.
  5. “Unknown”, “Others”, Missing and “Unclassified” are not included in the statistical analysis.
  6. eComparison of infiltrating ductal carcinoma (IDC) and infiltrating lobular carcinoma (ILC).
  7. fPatients enrolled from June 2005 (n = 725); HER2 testing was not performed routinely before this time point.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us